GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Forward Rate of Return (Yacktman) %

Amedisys (Amedisys) Forward Rate of Return (Yacktman) % : 0.00% (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Amedisys Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Amedisys's forward rate of return for was 0.00%.

The historical rank and industry rank for Amedisys's Forward Rate of Return (Yacktman) % or its related term are showing as below:

AMED' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.04   Med: 22.19   Max: 41.38
Current: 3.29

During the past 13 years, Amedisys's highest Forward Rate of Return was 41.38. The lowest was 3.04. And the median was 22.19.

AMED's Forward Rate of Return (Yacktman) % is ranked worse than
77.24% of 312 companies
in the Healthcare Providers & Services industry
Industry Median: 15.23 vs AMED: 3.29

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Amedisys Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Amedisys's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Forward Rate of Return (Yacktman) % Chart

Amedisys Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.19 21.66 23.53 27.10 3.03

Amedisys Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.91 15.10 8.61 3.03 -

Competitive Comparison of Amedisys's Forward Rate of Return (Yacktman) %

For the Medical Care Facilities subindustry, Amedisys's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amedisys's Forward Rate of Return (Yacktman) % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Amedisys's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Amedisys's Forward Rate of Return (Yacktman) % falls into.



Amedisys Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Amedisys's Forward Rate of Return of Mar. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=5.20209524/92.16+-0.079
=-2.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amedisys  (NAS:AMED) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Amedisys Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Amedisys's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amedisys (Amedisys) Business Description

Traded in Other Exchanges
Address
3854 American Way, Suite A, Baton Rouge, LA, USA, 70816
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Executives
Allyson Guidroz officer: Chief Accounting Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth director, officer: President and CEO 200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North officer: Chief Information Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton officer: Chief People Officer C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert officer: Chief Compliance Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato officer: Chief Strategy Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter director PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins director 500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard officer: Chief Operating Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout director 2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye director AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly officer: See Remarks 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816